Background pattern
Kengrexal 50 mg polvo para concentrado para solucion inyectable y para perfusion

Kengrexal 50 mg polvo para concentrado para solucion inyectable y para perfusion

About the medicine

How to use Kengrexal 50 mg polvo para concentrado para solucion inyectable y para perfusion

Introduction

Patient Information Leaflet

Kengrexal 50 mg powder for concentrate for solution for injection and for infusion

cangrelor

Read this leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, consult your doctor.
  • If you experience any side effects, consult your doctor, even if they are not listed in this leaflet. See section 4.

1.What Kengrexal is and what it is used for

2.What you need to know before you start using Kengrexal

3.How to use Kengrexal

4.Possible side effects

  1. Storage of Kengrexal

6.Contents of the pack and additional information

1. What is Kengrexal and how is it used

Kengrexal is an antiplatelet medication that contains the active ingredient cangrelor.

Platelets are very small blood cells that can clump together and help in blood clotting. Sometimes, clots can form inside a damaged blood vessel, such as an artery of the heart, and this can be very dangerous as the clot can interrupt blood flow (thrombotic event), producing a heart attack (myocardial infarction).

Kengrexal reduces platelet clumping and thus reduces the likelihood of a clot forming.

You have been prescribed Kengrexal because you have blocked blood vessels in your heart (coronary artery disease) and need an intervention (called percutaneous coronary intervention, PCI) to remove the blockage. During this procedure, you may have a stent implanted in the blood vessel to help keep it open. The use of Kengrexal reduces the risk of this procedure causing a clot that blocks the blood vessels again.

Kengrexal should only be used in adults.

2. What you need to know before starting to use Kengrexal

No use Kengrexal

-if you are allergic to cangrelor or any of the other components of this medication (listed in section 6).

  • if you have a disease that currently causes bleeding, such as bleeding in the stomach or intestines, or have a disease that increases the likelihood of uncontrolled bleeding (hemostasis disorder or irreversible coagulation disorders).
  • if you have recently undergone major surgery or have suffered any type of severe physical trauma, such as a bone fracture or a traffic accident.
  • if you have very high and uncontrolled blood pressure.
  • if you have ever had a stroke or a mini-stroke (also known as a transient ischemic attack, TIA) caused by temporary interruption of blood flow to the brain.

Warnings and precautions

Consult your doctor before starting to use Kengrexal if:

  • you have or may have a higher risk of bleeding. For example, if you have a disease that affects blood clotting or another disease that could increase the risk of bleeding, such as recent severe injury, recent surgical intervention, history of stroke or transient ischemic attack, or recent bleeding in the stomach or intestines;
  • you have kidney failure or require dialysis;
  • you have had any allergic reaction to Kengrexal or any of its components;
  • you have respiratory problems, such as asthma;
  • your doctor has informed you that you have intolerance to some sugars.

Children and adolescents

Kengrexal is not recommended for use in children and adolescents under 18 years old.

Other medications and Kengrexal

You may receive aspirin (AAS) while receiving treatment with Kengrexal or another type of antiplatelet medication (e.g., clopidogrel) before and after being treated with Kengrexal.

Inform your doctor if you are taking any medication that may increase the risk of adverse effects such as bleeding, including blood thinners (anticoagulants, e.g., warfarin).

Inform your doctor if you are taking, have taken recently, or may need to take any other medication.

Pregnancy and breastfeeding

If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication. Kengrexal is not recommended during pregnancy.

Driving and operating machinery

The effect of Kengrexal disappears quickly and it is unlikely to affect your ability to drive or operate machinery.

Kengrexal contains sodium and sorbitol

Sorbitol is a source of fructose. If you suffer from hereditary fructose intolerance (HFI), a rare genetic disease, you should not receive this medication. Patients with HFI cannot break down fructose, which can cause severe adverse effects.

Consult your doctor before receiving this medication if you suffer from HFI.

This medication contains less than 1 mmol of sodium (23 mg) per vial; it is essentially "sodium-free".

3. How to use Kengrexal

Your treatment with Kengrexal will be monitored by an experienced doctor who specializes in treating patients with heart disease. The doctor will decide how much Kengrexal you will receive and prepare the medication.

Kengrexal is administered through an injection, followed by an infusion (drip), into a vein. The dose administered depends on your weight. The recommended dose is:

  • 30 micrograms per kilogram of body weight per injection, followed immediately by
  • 4 micrograms per kilogram of body weight per minute per infusion (drip), for at least 2 hours. The doctor will decide if you need treatment for a longer period.

If you use more Kengrexal than you should

A healthcare professional will administer this medication to you. Your doctor will decide how to treat you, which may include suspending the medication and monitoring for signs of adverse effects.

In case of doubt, consult your doctor again.

4. Possible Adverse Effects

Like all medicines, this medicine may cause side effects, although not everyone will experience them.

If you experience side effects, you may need medical attention.

Inform your doctorimmediatelyif you notice any of the following:

  • Bleeding in any part of the body. Bleeding is a frequent side effect of Kengrexal treatment (it may affect up to 1 in 10people). Bleeding can be severeand fatal outcomes have been reported.
  • Allergic reaction (skin rash, itching, narrowing/swelling of the throat, swelling of the tongue or lips, difficulty breathing). An allergic reaction is a rare side effect of Kengrexal treatment (it may affect up to 1 in 1,000people) but can be potentially severe.

Frequent side effects: may affect up to 1 in 10people

  • You may experience smaller bruises in any part of the body (including small red bruises on the skin or under the skin at the injection site that cause swelling),
  • shortness of breath,
  • bleeding that reduces blood volume or the number of red blood cells,
  • discharge from the injection site or catheter.

Infrequent side effects: may affect up to 1 in 100people

  • Bleeding that produces fluid around the heart, blood in the thoracic cavity or bleeding from the nose, digestive tract, abdomen or urine or from the injection site or catheter,
  • increased levels of creatinine in the blood (identified in blood tests), indicating reduced kidney function,
  • changes in blood pressure,
  • skin rash, pruritus, urticaria,
  • hematoma at the puncture site of the vessel.

Rare side effects: may affect up to 1 in 1,000people

  • Bleeding that produces low platelet count or anemia,
  • bleeding in the eyes, brain (including stroke), pelvis and lungs,
  • bleeding from wounds,
  • swelling similar to a balloon in an artery or heart wall, affecting only some layers of the vessel wall,
  • severe allergic reactions,
  • reduced blood coagulation,
  • hematomas,
  • facial swelling.

Very rare side effects: may affect up to 1 in 10,000people

  • Bleeding under the skin or around the eyes,
  • infection at bleeding sites,
  • heavy menstrual bleeding,
  • bleeding from the penis, ear or pre-existing skin tumors.

Reporting side effects

If you experience any type of side effect, consult your doctor, even if it is a possible side effect that does not appear in this leaflet.

You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Usehttps://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.

5. Kengrexal Storage

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the label and on the box after EXP. The expiration date is the last day of the month indicated.

No special storage conditions are required.

Reconstituted solution: the powder must be reconstituted immediately before dilution and use. Do not refrigerate.

Diluted solution:From a microbiological point of view, the medication must be used immediately,unless the reconstitution and dilution method excludes the risk of microbiological contamination. If not used immediately, the storage times and conditions in use before use are the responsibility of the user.

6. Contents of the packaging and additional information

Kengrexal Composition

  • The active ingredient is cangrelor. Each vial contains 50mg of cangrelor.After reconstitution, 1ml of concentrate contains 10mg of cangrelor and after dilution, 1ml of solution contains 200micrograms of cangrelor.
  • The other components are mannitol, sorbitol, and sodium hydroxide for pH adjustment.

Product Appearance and Packaging Contents

Lyophilized powder for concentrate solution for injection and infusion in a glass vial.

Kengrexal is a white to off-white lyophilized powder.

Kengrexal is marketed in packs of 10 vials.

Marketing Authorization Holder

Chiesi Farmaceutici S.p.A.
Via Palermo, 26/A

43122 Parma

Italy

Responsible Person for Manufacturing

Diapharm GmbH & CO. KG

Am Mittelhafen 56

48155 Münster

Germany

For further information about this medicinal product, please contact the local representative of the marketing authorization holder:

Spain

Ferrer Farma, S.A.

Tel: +34 93 600 3700

Last Review Date of this Leaflet: January 2023

Other Sources of Information

The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.

---------------------------------------------------------------------------------------------------------------------------

This information is intended solely for healthcare professionals:

Kengrexal should be administered by a doctor with experience in acute coronary care or coronary intervention procedures and is intended for specialized use in a hospital and acute setting.

Dosage

The recommended dose of Kengrexal for patients undergoing ICP is a bolus intravenous injection of 30micrograms/kg followed immediately by an intravenous infusion of 4micrograms/kg/min. The bolus and infusion should be initiated before the procedure and should continue for at least two hours or for the duration of the procedure, whichever is longer. At the discretion of the doctor, the infusion may continue for a total of 4hours, see section 5.1.

Patients should be switched to oral P2Y12treatment for chronic treatment. To transition, a loading dose of oral P2Y12treatment (clopidogrel, ticagrelor, or prasugrel) should be administered immediately after discontinuing the cangrelor infusion. Alternatively, a loading dose of ticagrelor or prasugrel, but not clopidogrel, may be administered up to 30minutes before completing the infusion, see section 4.5.

Preparation Instructions

Kengrexal should be prepared using aseptic techniques.

The vial should be reconstituted immediately before dilution and use. Reconstitute each vial of 50mg by adding 5ml of sterile water for injection. Gently mix the vial until the contents are fully dissolved. Avoid vigorous mixing. Allow the foam to settle. Ensure that the contents of the vial are fully dissolved and that the reconstituted product is a clear, colorless to yellowish solution.

Do not use without dilution. Before administration, 5ml of reconstituted solution from each vial should be extracted and further dilutedwith 250ml of sodium chloride 9mg/ml (0.9%) solution or with 5% glucose solution for injection. Mix the bag well.

After reconstitution, the medicinal product should be visually inspected for the presence of particles.

Kengrexal is administered in a weight-based regimen consisting of an initial bolus injection followed by an intravenous infusion. The bolus and infusion should be administered from the infusion solution.

This dilution will produce a concentration of 200micrograms/ml and should be sufficient for at least twohours of administration, as needed. Patients weighing 100kg or more will require a minimum of two bags.

Talk to a doctor online

Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.

5.07 reviews
Doctor

Anna Moret

Dermatology18 years of experience

Dr. Anna Moret is a board-certified dermatologist and dermatovenereologist. She specialises in adult and pediatric dermatology, venereology, aesthetic skin care, and general medicine. Her consultations are evidence-based and tailored to each patient’s dermatological needs.

Dr. Moret provides expert evaluation and treatment for: • Skin conditions such as eczema, acne, rosacea, dermatitis, and psoriasis • Hair and scalp issues including hair loss, dandruff, and seborrheic dermatitis • Pediatric skin problems — from newborns to adolescents • Sexually transmitted infections (STIs) and dermatovenereology • Aesthetic concerns: skin ageing, non-invasive cosmetic treatments • Skin allergies and hypersensitivity reactions • Mole checks, lesion evaluation, and skin cancer screening • Skincare advice and personalised cosmeceutical routines

Combining dermatology with general medical knowledge, Dr. Moret offers comprehensive care that addresses both skin health and underlying conditions. She also holds certification from the Canadian Board of Aesthetic Medicine, ensuring an internationally aligned approach to aesthetic dermatology.

CameraBook a video appointment
5.043 reviews
Doctor

Alina Tsurkan

Family medicine12 years of experience

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including: • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections • Chronic diseases: hypertension, diabetes, thyroid disorders, elevated cholesterol, weight management • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness • Women’s health: menstrual irregularities, perimenopausal symptoms, preventive screening • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance

She also provides: • IMT medical certificates for driving licence exchange in Portugal • Personalised preventive care and wellness consultations • Interpretation of test results and medical reports • Follow-up care and medication review • Support in managing multiple coexisting conditions • Remote prescription management and medical documentation

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

CameraBook a video appointment
5.078 reviews
Doctor

Andrei Popov

General medicine6 years of experience

Dr. Andrei Popov is a licensed pain management specialist and general practitioner based in Spain. He provides expert online care for adults dealing with both chronic and acute pain, as well as a wide range of everyday health concerns.

He specialises in diagnosing and treating pain conditions that affect quality of life, including: • Chronic pain lasting more than 3 months • Migraines and recurring headaches • Neck, back, lower back, and joint pain • Post-traumatic pain following injury or surgery • Nerve-related pain, fibromyalgia, and neuralgia In addition to pain management, Dr. Popov helps patients with: • Respiratory infections (colds, bronchitis, pneumonia) • High blood pressure and metabolic conditions such as diabetes • Preventive care and routine health check-ups

Online consultations last up to 30 minutes and include a detailed symptom review, personalised treatment planning, and medical follow-up when needed.

Dr. Popov’s approach is rooted in evidence-based medicine, combined with individualised care tailored to each patient’s history, lifestyle, and clinical needs.

CameraBook a video appointment
5.017 reviews
Doctor

Yevgen Yakovenko

General surgery11 years of experience

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise: • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan. • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions. • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies. • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries. • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required. • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up. • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data. • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications: • 12+ years of clinical experience in university hospitals in Germany and Spain • International education: Ukraine – Germany – Spain • Member of the German Society of Surgeons (BDC) • Certified in radiological diagnostics and robotic surgery • Active participant in international medical conferences and research

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

CameraBook a video appointment
See all doctors

Stay informed and save on care

Get health tips, platform updates, and exclusive promos for subscribers.

Follow us on social media
FacebookInstagramTikTok